Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAVE mCRC: Avelumab plus Cetuximab in pre-treated RAS wild type metastatic colorectal cancer
2017-004392-32Phase 2Completed
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by University of Campania Luigi Vanvitelli. Primary endpoint: Overall survival. Started Oct 2020; status: completed.
02
Drugs
avelumabcetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2017-004392-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004392-32.